Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia.
Coronary artery disease, leading to myocardial infarction and ischaemia, affects millions of persons and is one of the leading causes of morbidity and mortality worldwide. Invasive techniques such as coronary artery bypass grafting are used to alleviate the sequelae of arterial occlusion. Unfortunately, restenosis or occlusion of the grafted conduit occurs over a time frame of months to years with a gradual reduction in patency, especially in vein grafts. The events leading to intimal hyperplasia (IH) formation involve numerous cellular and molecular components. Various cellular elements of the vessel wall are involved as are leucocyte-endothelial interactions that trigger the coagulation cascade leading to localized thrombus formation. Subsequent phenotypic modification of the medial smooth muscle cells and their intimal migration is the basis of the lesion formation that is thought to be propagated by an immune-mediated reaction. Despite intense scrutiny, the pathophysiology of IH remains an enigma. Although several growth factors, cytokines and numerous other biomolecules have been implicated and their relationship to prohyperplasia pathways such as the phosphatidyl-inositol 3-kinase (PI3K)-Akt pathway has been established, many pieces of the puzzle are still missing. An in-depth understanding of early vein graft adaptation and progression is necessary to improve the long-term prognosis and develop more effective therapeutic measures. In this review, we have critically evaluated and summarized the literature to elucidate and interlink the numerous established and emerging factors that play a key role in the development of IH leading to vein graft restenosis.
Mitra
Amit K
AK
Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, NE 68178, USA.
Gangahar
Deepak M
DM
Agrawal
Devendra K
DK
D001157:Arterial Occlusive Diseases / Q000209:etiology / Q000276:immunology / Q000401:mortality / Q000473:pathology; D001026:Coronary Artery Bypass / Q000009:adverse effects / Q000401:mortality; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000276:immunology* / Q000473:pathology; D006085:Graft Survival / Q000276:immunology*; D006133:Growth Substances / Q000276:immunology; D006801:Humans; D006965:Hyperplasia / Q000209:etiology / Q000276:immunology / Q000401:mortality / Q000473:pathology; D007111:Immunity, Cellular; D007962:Leukocytes / Q000276:immunology* / Q000473:pathology; D009203:Myocardial Infarction / Q000150:complications / Q000276:immunology / Q000401:mortality / Q000601:surgery; D051058:Oncogene Protein v-akt / Q000276:immunology; D019869:Phosphatidylinositol 3-Kinases / Q000276:immunology; D015398:Signal Transduction / Q000276:immunology*; D017539:Tunica Intima / Q000276:immunology* / Q000473:pathology
D006133:Growth Substances; D019869:Phosphatidylinositol 3-Kinases; D051058:Oncogene Protein v-akt